US Pharma MarketingMoonwalk raises $70M to test siRNA treatment for obesity
Moonwalk Biosciences raises $70M Series B to push MW-101, an siRNA obesity drug aimed at fat tissue, toward a 2027 trial start. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Moonwalk Biosciences is heading to the clinic with an obesity program and has raised $70 million for that goal, leaning into a shift in its approach to using genetic medicine.
The company, founded by former ...
Source: Endpoints News